Adalimumab may be comparable in efficacy to tofacitinib in the treatment of patients with rheumatoid arthritis, according to a new study published by Deakin et al in JAMA Network Open. In the OPAL study, investigators examined data from 852 patients with rheumatoid arthritis who started treatment with either 40 mg of adalimumab once every 14 days or 10 mg of tofacitinib daily between 2015 and 2021. The primary outcome was the difference in the mean disease activity scores in 28 joints using C-reactive proteins between both groups. The investigators found that patients who received tofacitinib experienced minor clinical benefits after 3 months of therapy compared with those who received adalimumab—with disease activity scores of 2.4 vs 2.6, respectively. However, after 9 months of follow-up, the researchers reported no significant statistical differences in the scores of patients in both groups (2.3 vs 2.3). The investigators concluded that treatment with either agent led to clinically meaningful improvements for patients with rheumatoid arthritis.